Inogen Inc Q3 FY2024 earnings call

• Driving topline growth: Achieved $89M in Q3 revenue with 6% Y/Y growth, led by B2B POC sales. DTC is becoming more profitable with a streamlined sales force and patient-first pilot programs in progress.
• Path to profitability: Generated $3M positive cash flow in Q3, second consecutive quarter of positive cash flow and adjusted EBITDA profitability. Efforts to improve gross margin through second sourcing, production streamlining, and quality control.
• Innovation pipeline: Launched Rove 4 POC with light weight, high oxygen output, and long battery life. Progress with Simeox discussions with FDA, awaiting clearance update.

In the third quarter of 2024, Inogen achieved total revenue of $89 million, reflecting 6% year-over-year growth. The B2B POC sales led the performance with over 20% year-over-year revenue growth for the second consecutive quarter. Direct-to-consumer sales saw year-over-year declines due to a downsized sales force but are becoming more profitable. Domestic B2B revenue increased 35.1% to $23.4 million, and international B2B revenue rose 26.2% to $32.3 million. Rental revenue decreased 13.1% to $13.9 million. Total gross margin was 46.5%, increasing 630 basis points year-over-year. Sales revenue gross margin was 47.2%, up 1,000 basis points, while rental revenue gross margin was 43.2%, down 990 basis points.

• Raised full-year 2024 revenue expectations to $329M-$331M, reflecting 4%-5% Y/Y growth.
• Expect gross margins in the low-to-mid 40s and adjusted EBITDA loss for the back half of 2024.
• Anticipate better DTC performance in 2025 with patient-first pilot program fully rolled out in H1 2025.

• Rising advertising costs due to election-related TV spot demand, leading to reduction of non-value campaigns.
• Regulatory uncertainty regarding Simeox FDA clearance impacting innovation timeline and financials.
• Impact of downsized DTC sales force on future growth prospects.

Q: Color on DTC sales force size, productivity, and strategy to return to growth.

A: Sales force is downsized, focusing on increased productivity per rep. Patient-first initiative and evaluation of advertising spend to drive growth.

Q: Expectations for top and bottom line 2025, cash flow sustainability.

A: Focus on strategic initiatives, managing P&L, cost of goods sold reduction, and working capital to maintain cash flow.

Q: DTC rep headcount stabilization timeline.

A: Rep count is managed for profitability, expecting stabilization in mid-2025.

Q: Simeox FDA clearance update.

A: Positive interactions with FDA, but no confirmation of filing; update upon clearance.

Q: Rove 4 reception across channels.

A: Rove 4 launched, more impact in 2025, influential in U.S. market, more for DTC side with potential upgrade to Rove 6.